The other products on the list are diphenylcyclopropenone, glycolic acid, squaric acid dibutyl ester and trichloroacetic acid, all of which are only for topical use.
In an email alert, the agency said it evaluated 10 others — hydroxyzine HCl, mannitol, methacholine chloride, metoclopramide HCl, nalbuphine HCl, potassium acetate, procainamide HCl, sodium bicarbonate, sodium nitroprusside and verapamil HCl — but those are not on the list “at this time.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.